Actively Recruiting
Needle-based Percutaneous Ablation of Liver Tumors.
Led by inTumo Therapeutics, Inc. · Updated on 2026-01-20
31
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1. Using a needle under image guidance, the liver tumor is accessed and INT001 is injected. Upon injection into tumor, does INT001 ablate/kill the tumor entirely? 2. What medical problems do participants experience when receiving INT001? Participants will: Receive INT001 on day 1. Visit the clinic day 7, 30 and 90. Receive lab tests during each visit and MRI on day 30 and 90.
CONDITIONS
Official Title
Needle-based Percutaneous Ablation of Liver Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary or secondary liver cancer
- ECOG Performance Status score of 0 - 2
- Age 18 years or older and under 100 years
- Life expectancy of 3 months or more
- Unsuitable for surgical resection or transplantation
- Ability to understand and sign informed consent
- Willingness and ability to follow study procedures and visits
You will not qualify if you...
- Decompensated liver function (Child-Pugh C, moderate to severe ascites, coagulopathy, or severe cirrhosis)
- Liver dysfunction signs: AST or ALT more than 5 times upper limit of normal, bilirubin level over 2.0 mg/dL
- Bleeding disorders
- Allergy or intolerance to contrast agents used in imaging
- Life-threatening serious extrahepatic disease
- Conditions preventing benefit or safety such as ongoing infection, renal dysfunction, or morbidity
- Significant medical or psychiatric illness
- Pregnant or breastfeeding or planning pregnancy within 6 months
- Participation in another study affecting treatment outcome
- Lesions without contrast uptake on CT or MR angiography
- Lesions not hypervascular on angiography
- Lack of CT or MR imaging at screening or inability/unwillingness to undergo MRI during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Koc University Hospital
Topkapı, Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
Research Team
R
Rahmi Oklu, MD, PhD
CONTACT
E
Erhan Bayburtluoglu, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here